Drugs / CYNK001-IV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04489420 | Oct 2020 → Aug 2021 | giant cell glioblastoma | Celularity Incorporated | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYNK001-IV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04489420 ↗ |
| Modality | Cell therapy | “NK cells derived from human placental CD34+ cells and culture-expanded” NCT04489420 ↗ |
| Route | Intravenous | “systemic cohort (IV) (intravenous)” NCT04489420 ↗ |